Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at Goldfinch
→ Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years. Having led Novadip’s autologous cell therapy through a Phase I/IIa trial in spinal fusion patients, founding CEO Jean-François Pollet decided it’s time to pass the reins to a more experienced chief executive. And Abbey — whose experience includes overseeing a Phase III trial, raising over $250 million in private financings and an IPO, and sealing several partnerships — fits the bill.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.